Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-04-20

FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for BOSULIF (bosutinib) submitted by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BOSULIF (bosutinib)

Snippet

SUPPL AP for BOSULIF (BOSUTINIB)